Proclara's $47 million Series E financing was led by existing investors, including private investors and Merieux Developpement. The financing will support further clinical development of NPT088, as well as the preclinical advancement of additional molecules toward the clinic. With completion of this financing, Proclara has raised more than $110 million to date.